

Datasheet: MCA1039GA

BATCH NUMBER 149349

Description:	RAT ANTI DOG CD8
Specificity:	CD8
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	YCATE55.9
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			1/50 - 1/100
Immunohistology - Frozen	▪			
Immunohistology - Paraffin			▪	
ELISA			▪	
Immunoprecipitation			▪	
Western Blotting			▪	
Immunofluorescence	▪			

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

Target Species	Dog
Product Form	Purified IgG - liquid
Preparation	Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.09% Sodium Azide (NaN ₃)

Carrier Free	Yes
Approx. Protein Concentrations	IgG concentration 1 mg/ml
Immunogen	Canine CD8 alpha chimaeric human IgG1 Fc fusion protein.
External Database Links	<p>UniProt: P33706 Related reagents</p> <p>Entrez Gene: 403157 CD8A Related reagents</p>
Fusion Partners	Spleen cells from immunised DA rat were fused with cells of the Y3/Ag1.2.3 rat myeloma cell line.
Specificity	<p>Rat anti Dog CD8 antibody, clone YCATE55.9 was clustered as Canine CD8 in the First Canine Leukocyte Antigen Workshop (Cobbold et al. 1994). YCATE55.9 reacts with a rat cell line transfected with cDNA for canine CD8α (Gorman et al. 1994) and blocks MHC class I dependant T-cell responses <i>in vitro</i> and <i>in vivo</i>.</p> <p>Rat anti Dog CD8, clone YCATE55.9 has been shown to deplete circulating CD8+ T cells when administered to dogs <i>in vivo</i>. (Watson et al. 1993) Reduced levels of circulating CD8+ T cells has been associated with decreased survival times for dogs with osteosarcoma (Biller et al. 2010).</p>
Flow Cytometry	Use 10ul of the suggested working dilution to label 1 x 10 ⁶ cells in 100ul.
References	<ol style="list-style-type: none"> 1. Cobbold, S. & Metcalfe, S. (1994) Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW). Tissue Antigens. 43 (3): 137-54. 2. Gorman, S.D. et al. (1994) Isolation and expression of cDNA encoding the canine CD4 and CD8 alpha antigens. Tissue Antigens. 43 (3): 184-8. 3. Watson, C.J. et al. (1993) CD4 and CD8 monoclonal antibody therapy: strategies to prolong renal allograft survival in the dog. Br J Surg. 80 (11): 1389-92. 4. Papadogiannakis, E.I. et al. (2009) Determination of intracellular cytokines IFN-gamma and IL-4 in canine T lymphocytes by flow cytometry following whole-blood culture. Can J Vet Res. 73 (2): 137-43. 5. Benyacoub, J. et al. (2003) Supplementation of food with <i>Enterococcus faecium</i> (SF68) stimulates immune functions in young dogs. J Nutr. 133: 1158-62. 6. Bird, R.C. et al. (2010) An autologous dendritic cell canine mammary tumor hybrid-cell fusion vaccine. Cancer Immunol Immunother. 60: 87-97. 7. Bund, D. et al. (2010) Canine-DCs using different serum-free methods as an approach to provide an animal-model for immunotherapeutic strategies. Cell Immunol. 263: 88-98. 8. Estrela-Lima, A. et al. (2010) Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates. BMC Cancer. 10: 256.

9. Huang, Y.C. *et al.* (2008) CD5-low expression lymphocytes in canine peripheral blood show characteristics of natural killer cells. [J Leukoc Biol. 84: 1501-10.](#)
10. Kornegay, J.N. *et al.* (2010) Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. [Mol Ther. 18: 1501-8.](#)
11. Pichavant, C. *et al.* (2010) Expression of dog microdystrophin in mouse and dog muscles by gene therapy. [Mol Ther. 18: 1002-9.](#)
12. Pinheiro, D. *et al.* (2011) Phenotypic and functional characterization of a CD4(+) CD25(high) FOXP3(high) regulatory T-cell population in the dog. [Immunology. 132: 111-22.](#)
13. Reis, A.B. *et al.* (2006) Phenotypic features of circulating leucocytes as immunological markers for clinical status and bone marrow parasite density in dogs naturally infected by *Leishmania chagasi*. [Clin Exp Immunol. 146: 303-11.](#)
14. Figueiredo, M.M. *et al.* (2014) Expression of Regulatory T Cells in Jejunum, Colon, and Cervical and Mesenteric Lymph Nodes of Dogs Naturally Infected with *Leishmania infantum*. [Infect Immun. 82: 3704-12.](#)
15. Costa-Pereira, C. *et al.* (2015) One-year timeline kinetics of cytokine-mediated cellular immunity in dogs vaccinated against visceral leishmaniasis. [BMC Vet Res. 11 \(1\): 92.](#)
16. Schaut, R.G. *et al.* (2016) Regulatory IgDhi B Cells Suppress T Cell Function via IL-10 and PD-L1 during Progressive Visceral Leishmaniasis. [J Immunol. Apr 13. pii: 1502678.](#)
[\[Epub ahead of print\]](#)
17. Tagawa, M. *et al.* (2016) Evaluation of Costimulatory Molecules in Peripheral Blood Lymphocytes of Canine Patients with Histiocytic Sarcoma. [PLoS One. 11 \(2\): e0150030.](#)
18. Riondato, F. *et al.* (2015) Analytical and diagnostic validation of a flow cytometric strategy to quantify blood and marrow infiltration in dogs with large b-cell lymphoma. [Cytometry B Clin Cytom. Dec 13. \[Epub ahead of print\]](#)
19. Cortese, L. *et al.* (2015) An immune-modulating diet increases the regulatory T cells and reduces T helper 1 inflammatory response in Leishmaniosis affected dogs treated with standard therapy. [BMC Vet Res. 11: 295.](#)
20. Miller, J. *et al.* (2015) Humoral and Cellular Immune Response in Canine Hypothyroidism. [J Comp Pathol. 153 \(1\): 28-37.](#)
21. Riondato, F. *et al.* (2016) Identification of a suitable internal control for fluorescence analysis on canine peripheral blood samples. [Vet Immunol Immunopathol. 172: 38-42.](#)
22. Martini, V. *et al.* (2015) Canine small clear cell/T-zone lymphoma: clinical presentation and outcome in a retrospective case series. [Vet Comp Oncol. Jun 3. \[Epub ahead of print\]](#)
23. Gelain, M.E. *et al.* (2014) CD44 in canine leukemia: analysis of mRNA and protein expression in peripheral blood. [Vet Immunol Immunopathol. 159 \(1-2\): 91-6.](#)
24. Duz AL *et al.* (2014) The TcI and TcII *Trypanosoma cruzi* experimental infections induce distinct immune responses and cardiac fibrosis in dogs. [Mem Inst Oswaldo Cruz. 109 \(8\): 1005-13.](#)
25. Munhoz, T.D. *et al.* (2016) Regulatory T cells in dogs with multicentric lymphoma: peripheral blood quantification at diagnosis and after initial stage chemotherapy [Arq. Bras. Med. Vet. Zootec., v.68, n.1, p.1-9, 2016](#)
26. Bonnefont-Rebeix, C. *et al.* (2016) Characterization of a novel canine T-cell line established from a spontaneously occurring aggressive T-cell lymphoma with large granular cell morphology. [Immunobiology. 221 \(1\): 12-22.](#)
27. Viana, K.F. *et al.* (2015) Setting the proportion of CD4+ and CD8+ T-cells co-cultured

- with canine macrophages infected with *Leishmania chagasi*. [Vet Parasitol. 211 \(3-4\): 124-32.](#)
28. Bromberek, J.L. *et al.* (2016) Breed Distribution and Clinical Characteristics of B Cell Chronic Lymphocytic Leukemia in Dogs. [J Vet Intern Med. 30 \(1\): 215-22.](#)
 29. Mie K *et al.* (2016) Influence of transfusion of lymphokine-activated T killer cells on inflammatory responses in dogs after laparotomy. [J Vet Med Sci. Jan 2. \[Epub ahead of print\]](#)
 30. Miglio, A. *et al.* (2014) Acute undifferentiated leukaemia in a dog. [Aust Vet J. 92 \(12\): 499-503.](#)
 31. Villaescusa, A. *et al.* (2015) Effects of doxycycline on haematology, blood chemistry and peripheral blood lymphocyte subsets of healthy dogs and dogs naturally infected with *Ehrlichia canis*. [Vet J. 204 \(3\): 263-8.](#)
 32. Fiuza JA *et al.* (2015) Vaccination using live attenuated *Leishmania donovani* centrin deleted parasites induces protection in dogs against *Leishmania infantum*. [Vaccine. 33 \(2\): 280-8.](#)
 33. Perosso, J. *et al.* (2014) Alteration of sFAS and sFAS ligand expression during canine visceral leishmaniasis. [Vet Parasitol. 205 \(3-4\): 417-23.](#)
 34. Heinrich, F. *et al.* (2015) Immunophenotyping of immune cell populations in the raccoon (*Procyon lotor*). [Vet Immunol Immunopathol. 168 \(3-4\): 140-6.](#)
 35. Poggi A *et al.* (2016) Prognostic significance of Ki67 evaluated by flow cytometry in dogs with high-grade B-cell lymphoma. [Vet Comp Oncol. Jan 21. \[Epub ahead of print\]](#)
 36. McGill, J.L. *et al.* (2016) Vaccination with an Attenuated Mutant of *Ehrlichia chaffeensis* Induces Pathogen-Specific CD4+ T Cell Immunity and Protection from Tick-Transmitted Wild-Type Challenge in the Canine Host. [PLoS One. 11 \(2\): e0148229.](#)
 37. Villaescusa, A. *et al.* (2012) Evaluation of peripheral blood lymphocyte subsets in family-owned dogs naturally infected by *Ehrlichia canis*. [Comp Immunol Microbiol Infect Dis. 35 \(4\): 391-6.](#)
 38. Schaut RG *et al.* (2016) Recovery of antigen-specific T cell responses from dogs infected with *Leishmania (L.) infantum* by use of vaccine associated TLR-agonist adjuvant. [Vaccine. 34 \(44\): 5225-5234.](#)
 39. Miranda, S. *et al.* (2007) Characterization of circulating lymphocyte subpopulations in canine leishmaniasis throughout treatment with antimonials and allopurinol. [Vet Parasitol. 144 \(3-4\): 251-60.](#)
 40. Viana, K.F. *et al.* (2016) Application of rapid in vitro co-culture system of macrophages and T-cell subsets to assess the immunogenicity of dogs vaccinated with live attenuated *Leishmania donovani* centrin deleted parasites (LdCen-/-). [Parasit Vectors. 9: 250.](#)
 41. Michael, H.T. *et al.* (2013) Isolation and characterization of canine natural killer cells. [Vet Immunol Immunopathol. 155 \(3\): 211-7.](#)
 42. Mitchell, L. *et al.* (2012) Induction of remission results in spontaneous enhancement of anti-tumor cytotoxic T-lymphocyte activity in dogs with B cell lymphoma. [Vet Immunol Immunopathol. 145 \(3-4\): 597-603.](#)
 43. DaSilva, A.V.A. *et al.* (2018) Morphophysiological changes in the splenic extracellular matrix of *Leishmania infantum*-naturally infected dogs is associated with alterations in lymphoid niches and the CD4+ T cell frequency in spleens. [PLoS Negl Trop Dis. 12 \(4\): e0006445.](#)
 44. Roatt, B.M. *et al.* (2017) A Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in

Parasite Burden. [Front Immunol. 8: 217.](#)

45. Aricò, A. *et al.* (2013) The role of vascular endothelial growth factor and matrix metalloproteinases in canine lymphoma: *in vivo* and *in vitro* study. [BMC Vet Res. 9: 94.](#)

46. Aguiar-Soares, R.D.O. *et al.* (2020) Phase I and II Clinical Trial Comparing the LBSap, Leishmune®, and Leish-Tec® Vaccines against Canine Visceral Leishmaniasis. [Vaccines \(Basel\). 8 \(4\)Nov 17 \[Epub ahead of print\].](#)

Storage

Store at +4°C or at -20°C if preferred.

This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.

Guarantee

12 months from date of despatch

Health And Safety Information

Material Safety Datasheet documentation #10040 available at: <https://www.bio-rad-antibodies.com/SDS/MCA1039GA10040>

Regulatory

For research purposes only

Related Products

Recommended Secondary Antibodies

Rabbit Anti Rat IgG (STAR16...)	DyLight®800
Rabbit Anti Rat IgG (STAR17...)	FITC
Goat Anti Rat IgG (STAR73...)	RPE
Rabbit Anti Rat IgG (STAR21...)	HRP
Goat Anti Rat IgG (MOUSE ADSORBED) (STAR71...)	DyLight®550 , DyLight®650 , DyLight®800
Goat Anti Rat IgG (STAR131...)	Alk. Phos. , Biotin
Goat Anti Rat IgG (STAR72...)	HRP
Goat Anti Rat IgG (STAR69...)	FITC

Recommended Negative Controls

[RAT IgG1 NEGATIVE CONTROL \(MCA6004GA\)](#)

North & South America	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com	Worldwide	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com	Europe	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com
----------------------------------	---	------------------	---	---------------	---

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)

'M364694:200529'

Printed on 23 May 2025